SOURCE: SuperSonic Imagine

SuperSonic Imagine

April 13, 2016 02:00 ET

SuperSonic Imagine to Demonstrate Its Non-Invasive, 60-Second Liver Assessment Exam at the International Liver Congress™ (ILC 2016) Barcelona, Spain

AIX-EN-PROVENCE, FRANCE--(Marketwired - Apr 13, 2016) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), the highly innovative ultrasound company, announced today that the clinical benefits of its real-time ShearWave™ Elastography (SWE™) technology for non-invasive assessment of patients with chronic liver disease will be presented while participating at the International Liver Congress, April 13th - 17th in Barcelona, Spain.

The Aixplorer® ultrasound system includes a 60-second ShearWave Elastography exam for helping physicians to screen, stage and monitor liver disease. 

During the conference, two key abstracts will be presented on SuperSonic Imagine's ShearWave Elastography and its effects on liver assessment.

  • Thursday, April 14, 12:06pm - 12:12pm (SAT-434) - Booth 4. Results of Professor Krag's and Professor Trebicka's study will be presented focusing on SWE's ability to accurately identify patients with clinical decompensation of liver cirrhosis.1

  • Friday, April 15, 4:30pm - 4:45pm (PS084) - Hall 8.0-B3: Professor Thierry Poynard will present his study conducted on 2251 patients with chronic liver diseases, demonstrating that stiffness measurements performed with SWE have a higher reliability than transient elastography.2

ShearWave Elastography is a non-invasive exam that provides a quantitative color-coded map to visualize and quantify tissue stiffness during an examination. Liver stiffness increases with the severity of liver fibrosis, making it a key parameter for physicians to stage fibrosis. Over 70 international publications have demonstrated the reliability and effectiveness of SuperSonic Imagine's SWE to assess the severity of chronic liver disease.

A recently published article in Hepatology3 compared SuperSonic Imagine's ShearWave technology, transient elastography and ARFI, for liver stiffness measurement in patients with nonalcoholic fatty liver disease (NAFLD) in a two-site study. This study on 291 patients, all with liver biopsy, concluded that diagnostic performance of SWE was higher than the ones of ARFI and transient elastography, especially for early stages of fibrosis. This superior reliability of SWE stiffness measurements compared to ARFI was also demonstrated, in normal and high BMI patients (>=30 kg/m²).

"The results from the abstracts to be presented as well as multiple previous clinical studies demonstrate the clinical advantages of our real-time ShearWave Elastography for the global management of patients with liver fibrosis," said Jacques Souquet, SuperSonic Imagine's Chief Innovation Officer and Founder. "Liver diseases such as NAFLD and NASH can be silent killers if undetected, and we are committed to bringing innovative solutions to help physicians to screen, stage and monitor liver disease."

The Company will be exhibiting and performing live demonstrations at booth #2200C during the International Liver Congress from April 14th - 16th.

1 -- Liver fibrosis evaluation using real-time shear wve elastography : applicability, association with activity and steatosis, and diagnostic performance. Direct comparisons with transient elastography using biomarkers as references. Thierry Poynard* 1 et al. Abstract PS084, ILC 2016.

2 -- Algorithm to rule-out clinically significant portal hypertension combining shearwave elastography of liver and spleen: a prospective multi-center study. Christian Jansen1 et al. Abstract SAT-434, ILC 2016.

3 -- Liver Stiffness in Nonalcoholic Fatty Liver Disease: A Comparison of Supersonic Shear Imaging, FibroScan, and ARFI With Liver Biopsy. Christophe Cassinotto et al. Hepatology. 2015 Dec 13. doi: 10.1002/hep.28394

About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.

Contact Information

  • Contact information:

    SuperSonic Imagine
    Chief Executive Officer
    Bernard Doorenbos
    Email Contact
    +33 6 15 66 64 68

    NewCap
    Investor Relations - EU
    Pierre Laurent / Florent Alba
    Email Contact
    +33 1 44 71 98 55

    SuperSonic Imagine
    Marketing & Communication
    Emmanuelle Vella
    Email Contact
    +33 4 86 79 03 27

    Pascale Communication
    Media Relations - US
    Amy Phillips
    Email Contact
    +1 412 327 9499